Why Caris Life Sciences, Inc.’s (CAI) Stock Is Down 5.72%
As of Friday, November 13, Caris Life Sciences, Inc.’s CAI share price has dipped by 5.72%, which has investors questioning if this is right time to buy.Jenna Brashear
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
Jenna Brashear
Rosalio Madrigal
Tudor Pop
Michael Rose
Rosalio Madrigal
| Share Statistics | CAI | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $6,607.5 | $211.8 | 72% |
|
| Shares Out (Mil) | 295.1 | 55.4 | 82% |
|
| Institutional Ownership | 55.5% | 93.0% | 37% |
|
| Float (Mil) | 139.1 | 41.5 | 67% |
|
| Beta | na | 0.99 | na |
|
| Avg Daily Volume (000s) | 4,939 | 553 | 91% |
|
| Price Change (52-week) |
(7.0%) | 42.8% | 44% |
|
| Growth | CAI | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.2% | na |
|
| Net Income (5yr) | na | (10.3%) | na |
|
| EPS (5yr) | na | 15.8% | na |
|
| Dividends (5yr) | na | 0.0% | 0% |
|
| Cash Flow (5yr) | na | (15.7%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 8 | 10 | 10 | |
| Current EPS | $0.060 | $0.114 | $0.291 | |
| Month Ago EPS | $0.112 | $0.137 | $0.368 | |
| # Rev Up | 0 | 2 | 0 | |
| # Rev Down | 0 | 0 | 1 | |
| Three Months Ago EPS | $0.109 | $0.144 | $0.378 | |
| Year/Year Chg | 20.0% | (103.5%) | (114.2%) | |
| Financials | CAI | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $1,048 | $41 | 50% |
|
| Net Income (TTM) (Mil) | $96 | ($44) | 60% |
|
| EPS (TTM) | $0.339 | ($1.500) | 49% |
|
| Operating Cash Flow (TTM) (Mil) | $84 | ($35) | 50% |
|
| Net Cash Flow (TTM) (Mil) | ($90) | $-0 | 16% |
|
| Long-Term Debt (Q1) (Mil) | $457 | $4 | 57% |
|
| Enterprise Value (Q1) (Mil) | $7,029 | $147 | 68% |
|
| Valuation | CAI | Industry Median |
Percentile (All Stocks) |
|
| P/B | 10.33 | 2.01 | 92% |
|
| P/E | 69.2 | 17.9 | 91% |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | CAI | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 69.3% | 67.9% | 80% |
|
| Net Margin | 9.2% | (50.6%) | 59% |
|
| ROA | 8.6% | (47.4%) | 83% |
|
| ROE | 17.2% | (53.1%) | 75% |
|
| Liabilities to Assets | 49.1% | 29.7% | 41% |
|
| F-Score | 3 | 3 | 18% |
|
Caris Life Sciences, Inc. did not pass any screens on 11/13/2026.
Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.
Ⓒ 2026 American Association of Individual Investors